Verastem (VSTM) EPS (Weighted Average and Diluted) (2016 - 2026)
Verastem (VSTM) recorded quarterly EPS (Weighted Average and Diluted) of -$0.46 in Q1 2026, down 58.62% quarter-over-quarter from -$0.29 in Q4 2025, and up 52.08% on a YoY basis from -$0.3 in Q1 2025.
Verastem (VSTM) EPS (Weighted Average and Diluted) (2016 - 2026) Analysis & Trends
Verastem's EPS (Weighted Average and Diluted) history runs 11 years deep, the most recent figure standing at -$0.46 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 52.08% year-over-year to -$0.46; the TTM figure through Mar 2026 stood at -$2.72 (up 20.47% YoY), while the FY2025 annual figure was -$3.02, up 17.49% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.46 for Q1 2026 at Verastem, down from -$0.29 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.08 in Q1 2023 to a low of -$4.27 in Q4 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.89 across 5 years, with a median of -$0.62 in 2025.
- The sharpest annual moves came in 2024 and 2025: EPS (Weighted Average and Diluted) plunged 1475.0% in 2024, then surged 81.29% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$4.27 in 2022, then surged by 75.88% to -$1.03 in 2023, then sank by 50.49% to -$1.55 in 2024, then surged by 81.29% to -$0.29 in 2025, then tumbled by 58.62% to -$0.46 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.46 (Q1 2026), -$0.29 (Q4 2025), and -$1.35 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Verastem | 407.42 Mn | 225.74 Mn | 15.90 Mn | -0.46 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.46 |
| Dec 31, 2025 | -0.29 |
| Sep 30, 2025 | -1.35 |
| Jun 30, 2025 | -0.62 |
| Mar 31, 2025 | -0.96 |
| Dec 31, 2024 | -1.55 |
| Sep 30, 2024 | -0.60 |
| Jun 30, 2024 | -0.31 |
| Mar 31, 2024 | -1.26 |
| Dec 31, 2023 | -1.03 |
| Sep 30, 2023 | -0.75 |
| Jun 30, 2023 | -1.37 |
| Mar 31, 2023 | -0.08 |
| Dec 31, 2022 | -4.27 |
| Sep 30, 2022 | -0.09 |
| Jun 30, 2022 | -0.12 |
| Mar 31, 2022 | -0.09 |
| Dec 31, 2021 | -4.59 |
| Sep 30, 2021 | -0.13 |
| Jun 30, 2021 | -0.10 |